The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and ...
These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...
The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for ...
The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...
The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, ...
Applying AI-enabled route scouting services allows drug developers to avoid pitfalls that can typically occur in drug ...
Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have ...
Alison has more than 35 years of broad experience delivering clinical trials to sponsors with a patient centric mindset.
Motif, a fast-growing company in the clinical research technology sector, has taken a significant step in expanding its ...
One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal ...